Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up
K Dahan, H Debiec, E Plaisier… - Journal of the …, 2017 - journals.lww.com
Randomized trials of rituximab in primary membranous nephropathy (PMN) have not been
conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals
(NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months
of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-
month therapy with NIAT and 375 mg/m 2 intravenous rituximab on days 1 and 8 (n= 37) or
NIAT alone (n= 38). Median times to last follow-up were 17.0 (interquartile range, 12.5–24.0) …
conducted. We undertook a multicenter, randomized, controlled trial at 31 French hospitals
(NCT01508468). Patients with biopsy-proven PMN and nephrotic syndrome after 6 months
of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-
month therapy with NIAT and 375 mg/m 2 intravenous rituximab on days 1 and 8 (n= 37) or
NIAT alone (n= 38). Median times to last follow-up were 17.0 (interquartile range, 12.5–24.0) …
以上显示的是最相近的搜索结果。 查看全部搜索结果